Management of the pregnant hepatitis B patient

Current Hepatitis Reports

Volumn 7, Issue 1, 2008, Pages 12-17

  Tran, Tram T ^a   Keeffe, Emmet B ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CD4 ANTIGEN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 10; INTERLEUKIN 5; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ANEMIA; BIRTH DEFECT; CHRONIC LIVER DISEASE; DISEASE TRANSMISSION; ENDEMIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; INTRAUTERINE INFECTION; NONHUMAN; PATIENT COUNSELING; PERINATAL PERIOD; PREGNANT WOMAN; PREMATURITY; REVIEW; RISK BENEFIT ANALYSIS; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 45349100860     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-008-0016-0     Document Type: Review

References (34)

1. World Health Organization: Hepatitis B. World Health Organization fact sheet 204 (revised Oct. 2000). Available at: http://who.int/inf-fs/en/ fact204.html.
2. Coleman PJ, McQuillan GM, Moyer LA, et al.: Incidence of hepatitis B virus infection in the United States - implications for vaccination strategies. J Infect Dis 1988, 178:1579-1584.
3. Margolis HS, Alter MJ, Hadler SC: Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991, 11:84-92.
4. Connolly JH, McClelland WM, O'Neill HJ, et al.: Hepatitis B virus infection in Northern Ireland 1970-1987. Ulster Med J 1989, 58:72-82.
5. Stevens CE, Beasley RP, Tsui J, et al.: Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
6. Xu ZY, Duan SC, Margolis HS, et al.: Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B. J Infect Dis 1995, 171:54-60.
7. Ngui SL, O'Connell S, Eglin RP, et al.: Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 1997, 176:1360-1365.
8. Lee SD, Lo KJ, Tsai YT, et al.: Maternal hepatitis B virus DNA in mother-infant transmission. Lancet 1989, 1:719.
9. Karthigesu VD, Allison LM, Ferguson M, et al.: A hepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg "a" determinant. J Med Virol 1999, 58:346-352.
10. Lin HH, Lee TY, Chen DS, et al.: Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987, 111:877-881.
11. Lazizi Y, Badur S, Perk Y: Selective unresponsiveness to HBsAg vaccine in newborns related with an in utero passage of hepatitis B virus DNA. Vaccine 1997, 15:1095-1100.
12. Gerety RJ: Maternal transmission of hepatitis B [letter]. N Engl J Med 1976, 295:170-171.
13. Chircu LV, Mattiaccu M, Schiano G, et al.: HBs and anti-HBs survey in mother/infant pairs [letter]. Lancet 1975, 2:706.
14. Xu DZ, Yan YP, Choi BC, et al.: Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002, 67:20-26.
15. Lin HH, Lee TY, Chen DS, et al.: Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987, 111:877-881.
16. Towers CV, Asrat T, Rumney P: The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001, 184:1514-1518.
17. Burk RD, Hwang LY, Ho GY, et al.: Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994, 170:1418-1423.
18. Lee SD, Lo KJ, Tsai YT, et al.: Role of caesarean section in prevention of mother-infant transmission of hepatitis B. Lancet 1988, 2;833-834.
19. Pao CC, Yao DS, Lin MY, et al.: Hepatitis B virus DNA in cervicovaginal cells. Arch Pathol Lab Med 1991, 115:607-609.
20. Zhang SL, Yue YF, Bai GQ, et al.: Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol 2004, 10:437-438.
21. Wang J, Zhu Q, Zhang X: Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chinese Med J 2002, 115:1510-1512.
22. Marion SA, Pastore MT, Pi DW, et al.: Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994, 140:734-736.
23. Andre FE, Zuckerman AJ: Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994, 44:144-151.
24. Hill JB, Sheffield JS, Kim MJ, et al.: Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002, 99:1049-1052.
25. •• CDC: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recomm Rep 2005, 54:1-23. An excellent, recently updated resource for vaccination protocols, recommendations, and clinical management.
26. Mast E, Mahoney F, Kane M, et al.: Hepatitis B vaccine. In Vaccines. Edited by Plotkin SA, Orenstein WA. Philadelphia: Saunders; 2004:299-337.
27. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
28. van Zonneveld M, van Nunen AB, Niesters HG, et al.: Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10:294-297.
29. •• Xu WM, Cui YT, Wang L, et al.: Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicentre, randomized, double-blind, placebo-controlled study [abstract]. Hepatology 2004, 40:272A. The largest randomized study performed thus far on treatment of the pregnant woman with chronic hepatitis B, suggesting that treatment to reduce maternal levels of viremia may benefit in reducing risk of intrauterine hepatitis B transmission.
30. •• Watts DH, Covington DL, Beckerman K, et al.: Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004, 191:985-992. The pregnancy registry for exposure to antiretroviral agents provides the largest follow-up on pregnancy exposure to this class of medications; it also provides safety and birth defect rates.
31. Moodley J, Moodley D, Pillay K, et al.: Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998, 178:1327-1333.
32. Tyzeka [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2006.
33. Lok ASF, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
34. Keeffe EB, Dieterich DT, Han SB, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.